AUSTIN, Texas, Sept. 18, 2024 /PRNewswire/ — With the presidential election less than two months away, new research published today by eHealth, Inc. (NASDAQ: EHTH) (eHealth.com), a leading private online health insurance marketplace, shows that Republicans and Democrats are united in their growing alarm at the rising cost of healthcare and are looking to the next president to address it. Continue reading
Nearly one third of concussions in professional American football are due to impacts from the facemask, a part of the helmet that has remained mostly unchanged in the last decade. In a new study presented at the International Research Council on Biomechanics of Injury conference today, researchers used data collected from instrumented mouthpieces worn by players in the National Football League (NFL) that measured head motion and found that facemasks are the most frequent location of impact on a player’s helmet in a subset of high severity impacts. The study findings suggest that facemask enhancements could help protect players and minimize injury risk. Continue reading
MEDSIR, a leading company dedicated to advancing independent clinical research in oncology on an international level and part of Oncoclínicas & Co, the largest oncology treatment group in Latin America with significant strength in the clinical and outpatient setting, showcased its groundbreaking research at this year’s European Society for Medical Oncology (ESMO) Congress held in Barcelona. The company presented 12 new studies that address various types of cancer, marking a significant scientific milestone for MEDSIR. Continue reading
In the oncology world, there’s been plenty to celebrate recently, with cancer deaths falling by 33% in the last 30 years. However, there’s still a lot of work to do in the war on cancer, with the 2024 World Cancer Congress in Geneva highlighting several issues, such as artificial intelligence (AI), conflict zones and crisis care taking center stage at the gathering. Continue reading
With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help healthcare journalists and consumers stay on top of the week’s most newsworthy and popular releases, here’s a recap of some major stories from the week that shouldn’t be missed. Continue reading
XRP Healthcare is taking bold steps to become a leader in the integration of artificial intelligence (AI) and blockchain within the healthcare industry. At the heart of this transformation is the launch of the company’s groundbreaking XRPH AI Chatbot, designed to provide personalized, region-specific healthcare advice. This AI-powered platform is available on XRP Healthcare’s newly launched websites XRPH.ai home to the chatbot, and XRPHealthcare.ai where it can also be accessed from its home page. Continue reading
As part of the second European leg of the “Light Up Your Rings campaign”, Huawei today held an unforgettable outdoor cardio party, with globally renowned fashion and fitness influencer Pamela Reif leading the challenge. Continue reading
Johnson & Johnson (NYSE: JNJ) announced today that 11 oral presentations from the Company’s industry-leading solid tumor portfolio and pipeline will be featured at the 2024 World Conference on Lung Cancer (WCLC) and the European Society for Medical Oncology (ESMO) 2024 Congress. Twenty-seven studies (23 company-sponsored and four investigator-initiated), including four late-breaking abstracts, will feature new data in lung, bladder, prostate, and colorectal cancers. Continue reading
Hilleman Laboratories has today announced that its partner Bharat Biotech, has successfully launched HILLCHOL®, a breakthrough oral cholera vaccine (OCV), achieving a significant global public health milestone. Continue reading
Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced Food and Drug Administration (FDA) approval of its in vitro diagnostic (IVD) TruSight™ Oncology (TSO) Comprehensive test and its first two companion diagnostic (CDx) indications. This single test interrogates over 500 genes to profile a patient’s solid tumor, helping to increase the likelihood of identifying an immuno-oncology biomarker or clinically actionable biomarkers that enable targeted therapy options or clinical trial enrollment. Continue reading